Urothelial carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant neoplasm derived from the transitional epithelium of the urinary tract (urinary bladder, ureter, urethra, or renal pelvis). It is frequently papillary.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Urothelial carcinoma
- Therapeutic area
- Oncology
- urothelial carcinoma
- Uroepithelial carcinoma
- transitional cell car. -uroth.
- transitional cell carcinoma of the urinary tract
- transitional cell carcinoma of the urothelial tract
- urothelial carcinoma
- Severity
- Severe
- Nephrology
- Oncology
- MONDO ID
- MONDO:0040679
- Parent condition
- MONDO:0006295
Related records
Broader conditions (16)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Malignant urinary system neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Transitional cell carcinoma
- Transitional cell neoplasm
- Urinary system disorder
- Urinary system neoplasm
- Urothelial neoplasm
Narrower conditions (27)
- Bladder carcinoma in situ
- Bladder papillary urothelial carcinoma
- Bladder sarcomatoid transitional cell carcinoma
- Bladder transitional cell carcinoma
- Bladder urachal urothelial carcinoma
- Infiltrating bladder lymphoepithelioma-like carcinoma
- Infiltrating bladder urothelial carcinoma
- Infiltrating bladder urothelial carcinoma sarcomatoid variant
- Infiltrating bladder urothelial carcinoma, clear cell variant
- Infiltrating renal pelvis transitional cell carcinoma
- Infiltrating ureter transitional cell carcinoma
- Kidney pelvis sarcomatoid transitional cell carcinoma
- Lipid-cell variant infiltrating bladder urothelial carcinoma
- Lymphoma-like variant infiltrating bladder urothelial carcinoma
- Microcystic variant infiltrating bladder urothelial carcinoma
- Micropapillary variant infiltrating bladder urothelial carcinoma
- Nested variant infiltrating bladder urothelial carcinoma
- Non-invasive bladder urothelial carcinoma
- Non-papillary transitional cell carcinoma of the bladder
- Plasmacytoid variant infiltrating bladder urothelial carcinoma
Trials (475)
- 18F-LN1 PET/CT in Urothelial Carcinomas
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
- 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
- 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
- 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
- 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma
- A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.
- A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma
- A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
- A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
- A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
- A Multicenter Cancer Biospecimen Collection Study
- A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
- A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
- A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
- A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma
Approved drugs (3)
- Atezolizumab
- Avelumab
- Erdafitinib
Drugs in development (100)
- Aldesleukin Phase 2
- Amcasertib Phase 2
- Batiraxcept Phase 1
- Belinostat Phase 1
- Bevacizumab Phase 2
- Bicalutamide Phase 2
- Cabazitaxel Phase 2
- Cabozantinib Phase 2
- Cabozantinib S-malate Phase 1
- Cadonilimab Phase 2
- Capecitabine Phase 1
- Carboplatin Phase 3
- Cetrelimab Phase 3
- Cirmtuzumab Phase 1
- Cisplatin Phase 3
- Cobimetinib fumarate Phase 1
- Copanlisib Phase 1
- Cyclophosphamide Phase 1
- Derazantinib Phase 1
- Dexamethasone Phase 2
Other linked drugs (1)
- Enfortumab